Osivax Secures $10M Series B to Fast-Track Universal Respiratory Virus Vaccines Breakthrough

Osivax is excited to announce a major milestone in its pursuit of innovative vaccine solutions by raising $10,000,000 in its latest funding round. This significant capital infusion reinforces our commitment to advancing the development of cutting-edge pan-respiratory virus vaccines using our proprietary oligoDOM technology. As a clinical-stage biopharmaceutical company, Osivax is dedicated to leveraging its unique self-assembling nanoparticle platform to create transformative, first-in-class vaccine candidates that stimulate both robust T-cell responses and strong, sustained B-cell responses. Our current portfolio includes the groundbreaking OVX836, a broad-spectrum “universal” influenza candidate currently in Phase 2 clinical trials. With over 1,200 subjects tested, OVX836 has already demonstrated encouraging proof-of-concept efficacy data, underscoring the promise of our approach in combating influenza. The funds raised will be strategically allocated to expand our clinical development efforts and accelerate the advancement of OVX836 toward regulatory milestones. Additionally, this investment will empower Osivax to explore novel combinations and collaborations on a global scale, further expanding our pipeline into other infectious disease indications. Our overarching ambition is to develop a pan-respiratory virus vaccine that not only prevents all strains of influenza but also targets all variants of sarbecovirus with a single shot. This bold vision aims to revolutionize the field of vaccinology and enhance global public health measures. The support from our investors is a strong vote of confidence in our technology and mission, and we are eager to propel our research forward in pursuit of these transformative healthcare solutions.